PRNAF
Price:
$0.0036
Market Cap:
$29.45M
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.[Read more]
Industry
Biotechnology
IPO Date
2012-09-25
Stock Exchange
PNK
Ticker
PRNAF
According to Alterity Therapeutics Limited’s latest financial reports and current stock price. The company's current Current Ratio is 3.54. This represents a change of -16.03% compared to the average of 4.22 of the last 4 quarters.
The mean historical Current Ratio of Alterity Therapeutics Limited over the last ten years is 9.11. The current 3.54 Current Ratio has changed 3.79% with respect to the historical average. Over the past ten years (40 quarters), PRNAF's Current Ratio was at its highest in in the September 2015 quarter at 16.39. The Current Ratio was at its lowest in in the March 2024 quarter at 3.54.
Average
9.11
Median
7.06
Minimum
3.54
Maximum
15.88
Discovering the peaks and valleys of Alterity Therapeutics Limited Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 123.93%
Maximum Annual Current Ratio = 15.88
Minimum Annual Increase = -55.56%
Minimum Annual Current Ratio = 3.54
Year | Current Ratio | Change |
---|---|---|
2024 | 3.54 | -42.61% |
2023 | 6.17 | -12.68% |
2022 | 7.07 | -35.25% |
2021 | 10.92 | 123.93% |
2020 | 4.88 | -18.50% |
2019 | 5.98 | -15.22% |
2018 | 7.06 | -55.56% |
2017 | 15.88 | 11.20% |
2016 | 14.28 | -7.01% |
2015 | 15.35 | 46.03% |
The current Current Ratio of Alterity Therapeutics Limited (PRNAF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
5.59
5-year avg
6.52
10-year avg
9.11
Alterity Therapeutics Limited’s Current Ratio is greater than Genprex, Inc. (0.86), greater than Reviva Pharmaceuticals Holdings, Inc. (0.41), less than Greenwich LifeSciences, Inc. (6.91), greater than Cognition Therapeutics, Inc. (2.11), less than Gracell Biotechnologies Inc. (7.73), less than Galectin Therapeutics Inc. (0), greater than Northwest Biotherapeutics, Inc. (1.13), greater than CEL-SCI Corporation (0.09), greater than Tonix Pharmaceuticals Holding Corp. (0.64), greater than Jaguar Health, Inc. (3.33), greater than Acasti Pharma Inc. (1.84), less than Diffusion Pharmaceuticals Inc. (7.86), less than iBio, Inc. (10.96), greater than Vaxart, Inc. (3.37), greater than Novavax, Inc. (0.83), greater than Ocugen, Inc. (0.93), greater than CohBar, Inc. (2.58), less than Rain Therapeutics Inc. (15.69), less than Viking Therapeutics, Inc. (5.58), less than TG Therapeutics, Inc. (36.47), less than X4 Pharmaceuticals, Inc. (4.59), less than PDS Biotechnology Corporation (4.89), greater than Madrigal Pharmaceuticals, Inc. (0.00), less than null (5.98),
Company | Current Ratio | Market cap |
---|---|---|
0.86 | $9.36M | |
0.41 | $38.12M | |
6.91 | $178.11M | |
2.11 | $17.77M | |
7.73 | $989.87M | |
0 | $174.48M | |
1.13 | $355.50M | |
0.09 | $38.02M | |
0.64 | $35.51M | |
3.33 | $12.27M | |
1.84 | $34.17M | |
7.86 | $8.98M | |
10.96 | $24.15M | |
3.37 | $136.49M | |
0.83 | $1.36B | |
0.93 | $264.34M | |
2.58 | $1.45M | |
15.69 | $44.01M | |
5.58 | $5.86B | |
36.47 | $5.46B | |
4.59 | $57.64M | |
4.89 | $78.19M | |
0.00 | $7.58B | |
5.98 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alterity Therapeutics Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Alterity Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Alterity Therapeutics Limited's Current Ratio?
How is the Current Ratio calculated for Alterity Therapeutics Limited (PRNAF)?
What is the highest Current Ratio for Alterity Therapeutics Limited (PRNAF)?
What is the 3-year average Current Ratio for Alterity Therapeutics Limited (PRNAF)?
What is the 5-year average Current Ratio for Alterity Therapeutics Limited (PRNAF)?
How does the current Current Ratio for Alterity Therapeutics Limited (PRNAF) compare to its historical average?